TNFRSF9 and chronic hepatitis: We previously reported that repetitive injections of the agonist anti-CD137 mAb in HBV-transgenic mice consistently induced chronic hepatitis, fibrosis, cirrhosis, and, ultimately, adenoma and liver cancer, which closely mimics the pathogenic process of HCC developed from chronic hepatitis[29].